S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Axonics Stock Forecast, Price & News

-0.17 (-0.31%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
745,794 shs
Average Volume
532,002 shs
Market Capitalization
$2.51 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AXNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

Axonics logo

About Axonics

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.


Axonics (NASDAQ:AXNX) Trading Down 5.9%
November 29, 2021 |  americanbankingnews.com
Axonics (NASDAQ:AXNX) and CVRx (NASDAQ:CVRX) Head-To-Head Comparison
November 23, 2021 |  americanbankingnews.com
Axonics® Reports Third Quarter 2021 Financial Results
November 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$111.54 million
Book Value
$7.22 per share


Net Income
$-54.92 million
Pretax Margin




Free Float
Market Cap
$2.51 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.28 out of 5 stars

Medical Sector

295th out of 1,392 stocks

Surgical & Medical Instruments Industry

31st out of 127 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Axonics (NASDAQ:AXNX) Frequently Asked Questions

Is Axonics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Axonics stock.
View analyst ratings for Axonics
or view top-rated stocks.

How has Axonics' stock been impacted by Coronavirus (COVID-19)?

Axonics' stock was trading at $30.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AXNX stock has increased by 79.5% and is now trading at $54.24.
View which stocks have been most impacted by COVID-19

When is Axonics' next earnings date?

Axonics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Axonics

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.05. The firm earned $46.91 million during the quarter, compared to the consensus estimate of $48.39 million. Axonics had a negative net margin of 47.08% and a negative trailing twelve-month return on equity of 17.83%. The firm's revenue was up 33.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.24) earnings per share.
View Axonics' earnings history

What guidance has Axonics issued on next quarter's earnings?

Axonics issued an update on its fourth quarter 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $49.80 million-$49.80 million, compared to the consensus revenue estimate of $57.37 million.

What price target have analysts set for AXNX?

6 equities research analysts have issued twelve-month price targets for Axonics' stock. Their forecasts range from $65.00 to $85.00. On average, they expect Axonics' stock price to reach $74.83 in the next twelve months. This suggests a possible upside of 38.0% from the stock's current price.
View analysts' price targets for Axonics
or view top-rated stocks among Wall Street analysts.

Who are Axonics' key executives?

Axonics' management team includes the following people:

What is Raymond W. Cohen's approval rating as Axonics' CEO?

12 employees have rated Axonics CEO Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among Axonics' employees.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Honeywell International (HON), (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Who are Axonics' major shareholders?

Axonics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.32%), Credit Suisse AG (4.77%), Lord Abbett & CO. LLC (3.75%), Bamco Inc. NY (3.68%), Bellevue Group AG (3.47%) and AXA S.A. (3.30%). Company insiders that own Axonics stock include Alfred J Ford Jr, Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, John Woock, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends for Axonics

Which major investors are selling Axonics stock?

AXNX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Credit Suisse AG, Sectoral Asset Management Inc, Lord Abbett & CO. LLC, AXA S.A., Bellevue Group AG, Macquarie Group Ltd., and Principal Financial Group Inc.. Company insiders that have sold Axonics company stock in the last year include Alfred J Ford Jr, Danny L Dearen, John Woock, Raymond W Cohen, Rinda Sama, and Robert E Mcnamara.
View insider buying and selling activity for Axonics
or view top insider-selling stocks.

Which major investors are buying Axonics stock?

AXNX stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., BlackRock Inc., Victory Capital Management Inc., Dimensional Fund Advisors LP, Invesco Ltd., CastleArk Alternatives LLC, Ziegler Capital Management LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Axonics
or or view top insider-buying stocks.

How do I buy shares of Axonics?

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $54.24.

How much money does Axonics make?

Axonics has a market capitalization of $2.51 billion and generates $111.54 million in revenue each year. The company earns $-54.92 million in net income (profit) each year or ($1.83) on an earnings per share basis.

How many employees does Axonics have?

Axonics employs 416 workers across the globe.

What is Axonics' official website?

The official website for Axonics is www.axonics.com.

Where are Axonics' headquarters?

Axonics is headquartered at 26 TECHNOLOGY DRIVE, IRVINE CA, 92618.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at (866) 722-5738, via email at [email protected], or via fax at 949-396-6321.

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.